These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 8894583

  • 21. Postantibiotic effect of a combination of antimicrobial agents on pseudomonas aeruginosa.
    Sood P, Mandal A, Mishra B.
    Chemotherapy; 2000; 46(3):173-6. PubMed ID: 10765031
    [Abstract] [Full Text] [Related]

  • 22. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
    Montanari MP, Prenna M, Mingoia M, Ripa S, Varaldo PE.
    Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Activities of clinafloxacin, alone and in combination with other compounds, against 45 gram-positive and -negative organisms for which clinafloxacin MICs are high.
    Clark CL, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2295-8. PubMed ID: 10471582
    [Abstract] [Full Text] [Related]

  • 26. Comparative activity of meropenem (SM-7338) against major respiratory pathogens and amikacin-resistant nosocomial isolates.
    Sarubbi F, Franzus B, Verghese A.
    Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):65-8. PubMed ID: 1563388
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. The in-vitro activity of trovafloxacin and nine other antimicrobials against 413 anaerobic bacteria.
    Bowker KE, Wootton M, Holt HA, Reeves DS, MacGowan AP.
    J Antimicrob Chemother; 1996 Aug; 38(2):271-81. PubMed ID: 8877542
    [Abstract] [Full Text] [Related]

  • 30. Synergic activity, for anaerobes, of trovafloxacin with clindamycin or metronidazole: chequerboard and time-kill methods.
    Ednie LM, Credito KL, Khantipong M, Jacobs MR, Appelbaum PC.
    J Antimicrob Chemother; 2000 May; 45(5):633-8. PubMed ID: 10797085
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Comparative in vitro activity of gemifloxacin.
    King A, May J, French G, Phillips I.
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():1-12. PubMed ID: 10824026
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. In vitro and in vivo synergy of levofloxacin or amikacin both in combination with ceftazidime against clinical isolates of Pseudomonas aeruginosa.
    Piccoli L, Guerrini M, Felici A, Marchetti F.
    J Chemother; 2005 Aug; 17(4):355-60. PubMed ID: 16167512
    [Abstract] [Full Text] [Related]

  • 39. New antibiotics.
    Friedland IR, Lutsar I.
    Curr Opin Pediatr; 1998 Feb; 10(1):41-5. PubMed ID: 9529636
    [Abstract] [Full Text] [Related]

  • 40. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates.
    Felmingham D, Robbins MJ, Ingley K, Mathias I, Bhogal H, Leakey A, Ridgway GL, Grüneberg RN.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():43-9. PubMed ID: 9222069
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.